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Objectives
To test the feasibility of a randomised trial in muscle-invasive
bladder cancer (MIBC) and compare outcomes in patients
who receive neoadjuvant chemotherapy followed by radical
cystectomy (RC) or selective bladder preservation (SBP),
where deﬁnitive treatment [RC or radiotherapy (RT)] is
determined by response to chemotherapy.
Patients and Methods
SPARE is a multicentre randomised controlled trial
comparing RC and SBP in patients with MIBC staged T2–3
N0 M0, ﬁt for both treatment strategies and receiving three
cycles of neoadjuvant chemotherapy. Patients were
randomised between RC and SBP before a cystoscopy after
cycle three of neoadjuvant chemotherapy. Patients with ≤T1
residual tumour received a fourth cycle of neoadjuvant
chemotherapy in both groups, followed by radical RT in the
SBP group and RC in in the RC group; non-responders in
both groups proceeded immediately to RC following cycle
three. Feasibility study primary endpoints were accrual rate
and compliance with assigned treatment strategy. The phase
III trial was designed to demonstrate non-inferiority of SBP
in terms of overall survival (OS) in patients whose tumours
responded to neoadjuvant chemotherapy. Secondary
endpoints included patient-reported quality of life, clinician
assessed toxicity, loco-regional recurrence-free survival, and
rate of salvage RC after SBP.
Results
Trial recruitment was challenging and below the predeﬁned
target with 45 patients recruited in 30 months (25 RC; 20
SBP). Non-compliance with assigned treatment strategy was
frequent, six of the 25 patients (24%) randomised to RC
received RT. Long-term bladder preservation rate was 11/15
(73%) in those who received RT per protocol. OS survival
was not signiﬁcantly different between groups.
Conclusions
Randomising patients with MIBC between RC and SBP based
on response to neoadjuvant chemotherapy was not feasible in
the UK health system. Strong clinician and patient
preferences for treatments impacted willingness to undergo
randomisation and acceptance of treatment allocation. Due to
the few participants, ﬁrm conclusions about disease and
toxicity outcomes cannot be drawn.
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Introduction
Achieving local disease control is a critical step in treating
muscle-invasive bladder cancer (MIBC). A common approach
is surgical removal of the bladder and adjacent organs, i.e.
radical cystectomy (RC). Despite being a successful approach
to cancer control, this is a major operation, in an often unﬁt
and/or elderly population. It requires formation of a urinary
diversion and has substantial associated morbidity and
mortality rates [1,2].
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Radical radiotherapy (RT) is an alternative to RC [3,4]. It
preserves a functioning bladder and avoids the risks of major
surgery, but does not achieve local control for all patients
and, if unsuccessful, requires subsequent salvage RC, which
can be challenging [5]. The relative efﬁcacy of RT and RC
has been debated extensively but, as randomised data are
lacking, comparisons have been largely based on retrospective
series, where inherent biases can make interpretation difﬁcult
[4,6,7]. UK bladder cancer treatment guidelines released in
2015 recommend that patients with MIBC are offered a
choice of RC or RT with a radiosensitiser [8].
There also exists a paucity of comparative data on the effects
of both treatment options on patients’ quality of life. RC has
been found to have a substantial negative impact on health-
related quality of life in the ﬁrst year postoperatively [4],
whilst patients who have received RT experience greater
gastrointestinal dysfunction [9].
Several groups have hypothesised that RT would be more
attractive as a treatment option if it were possible to select
patients with tumours most likely to respond. This would
minimise the need for salvage RC by undertaking immediate
RC for patients predicted to have less chance of cure with RT.
Neoadjuvant chemotherapy before radical treatment improves
survival in MIBC [10,11] and studies have suggested that
tumours that respond to neoadjuvant chemotherapy may
achieve higher rates of local control with RT than those
which do not [11,12]. Using chemotherapy in this way to
select patients for RT achieved high levels of long-term
bladder preservation and avoided the need for surgery in
most patients [13,14]. To test the efﬁcacy of this approach we
planned a randomised trial, with an initial feasibility study to
compare, after neoadjuvant chemotherapy, a selective bladder
preservation (SBP) strategy with patients undergoing RC.
Patients and Methods
Study Design
SPARE (CRUK/07/011) was a multicentre phase III
randomised controlled trial with an initial feasibility study
(Fig. 1). The aims of the feasibility study were to determine
viability of accrual for the phase III trial and assess
compliance with the assigned treatment strategy. There was
an embedded qualitative research programme, which has been
previously reported [15,16]. The phase III trial was designed
to determine if overall survival (OS) following bladder
preservation is non-inferior to that following RC for patients
whose tumours respond to neoadjuvant chemotherapy.
Patients were recruited at UK NHS Trusts. All Trusts
providing trial treatment had to provide details of surgical
activity, including morbidity and mortality rates, for central
review and conﬁrmation of completion of a RT quality
assurance programme prior to activation. Randomisation was
by telephone to the Institute of Cancer Research, Clinical
Trials and Statistics Unit (ICR-CTSU). Participants were
assigned 1:1 between SBP and RC using computer-generated
random permuted blocks (size 6 and 8), stratiﬁed by centre.
Treatment allocation was not masked.
Patients
Eligible patients provided written informed consent, were
receiving neoadjuvant chemotherapy and ﬁt for RT and RC,
aged ≥18 years, had T2–T3 N0 M0 TCC of the bladder and
WHO performance status of 0–1, with satisfactory
haematological proﬁle and kidney function. Key exclusion
criteria were widespread carcinoma in situ; simultaneous upper
tract, urethral or prostatic urethral TCC; untreated
hydronephrosis; and invasive malignancy in the previous 5 years.
Initially treatment allocation took place during cycle two of
neoadjuvant chemotherapy. Based on ﬁndings of the
qualitative recruitment investigation [16], this timeframe was
amended in August 2009 to allow randomisation at any time
prior to a cystoscopy after chemotherapy cycle three (CT3) of
neoadjuvant chemotherapy.
Treatments
All patients received neoadjuvant chemotherapy. Gemcitabine
(1 000 mg/m2 day 1 and day 8) and cisplatin (70 mg/m2)
repeated every 21 days was recommended. All patients had a
cystoscopy and tumour bed biopsy under general anaesthetic
after CT3 of neoadjuvant chemotherapy, with subsequent
treatment dependent on response.
Patients with ≥pT2 disease in both randomised groups
proceeded immediately to RC within 6 weeks of CT3.
Patients with histological downstaging (≤pT1), or a
macroscopically normal bladder were classiﬁed as responders
and received chemotherapy cycle 4 (CT4) of neoadjuvant
chemotherapy with subsequent treatment determined by
randomised allocation. Patients receiving RT were permitted
to receive concomitant radiosensitising chemotherapy.
SBP Group
Patients whose tumours responded to neoadjuvant
chemotherapy started RT to the bladder 4–6 weeks after CT4.
Two fractionation schedules in standard use in the UK were
permitted (55 Gy/20 fractions or 64 Gy/32 fractions). The
planning target volume was the bladder plus 1.5 cm margin,
delivered by three-dimensional conformal techniques.
RC Group
Patients whose tumours responded to neoadjuvant
chemotherapy received RC 4–6 weeks after CT4. RC
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consisted of resection of the bladder, prostate and seminal
vesicles in men and bladder, uterus, ovaries and upper vagina
in women. Pelvic lymphadenectomy, removing a minimum of
10 lymph nodes, was mandated and recommended to include
dissection of the obturator nodes and external iliac nodes to
the level of the iliac bifurcation and internal iliac nodes from
the right and left side of the pelvis. The lateral limit of the
dissection was the genito-femoral nerve on the psoas muscle,
and medial and posterior limits represented by the obturator
nodes.
Orthotopic reconstruction using small or large bowel was
encouraged; however, standard ileal conduit formation was
also permitted.
Trial Assessments
Before neoadjuvant chemotherapy, patients underwent
physical examination, haematological and biochemical
assessment, CT of the pelvis, chest X-ray or CT, and maximal
cystoscopic resection of tumour. Tumour control was assessed
by physical examination, chest X-ray and cystoscopy (if
applicable) with follow-up as shown in Figure 1. Adverse
events were graded using Common Terminology Criteria for
Adverse Events (CTCAE) version 3 [17]. Patient-reported
outcomes were collected, using paper European Organisation
for the Research and Treatment of Cancer (EORTC) general
cancer and MIBC modules [quality of life questionnaire – 30-
item core (QLQ-C30) and 30-item quality of life
questionnaire for patients with muscle-invasive bladder cancer
(QLQ-BLM30)] [18].
Statistical Considerations
Endpoints
The primary endpoints of the feasibility study were accrual
rate, bladder preservation rate in the SBP arm, and RC rate
in the RC arm. For the phase III component, the primary
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endpoint was 5-year survival. Secondary endpoints were
treatment compliance, rate of salvage RC, toxicity, patient-
reported quality of life, and loco-regional recurrence-free
survival, and metastasis-free survival (MFS). For this analysis
OS was treated as a secondary endpoint.
Sample size
The phase III trial was powered to evaluate non-inferiority in
the proportion of patients alive at 5 years between SBP and
RC in those patients whose tumours responded to
neoadjuvant chemotherapy. A 70% 5-year survival was
assumed [13], with the aim of excluding a decrease of ≥8% in
the selective SBP group (corresponding to a critical hazard
ratio for non-inferiority of 1.34). Assuming an 80%
neoadjuvant chemotherapy response rate, 1 015 patients
would have been required to conclude non-inferiority (80%
power, one-sided a = 0.05). For the phase III study to be
considered feasible, it was recommended that 110 patients be
randomised during the ﬁrst 2 years; however, this was
amended to 3 years, or a sustainable accrual rate of at least
six patients per month, in August 2009 with the endorsement
of the independent Trial Steering Committee [16]. An
analysis of the feasibility stage was planned to assess
compliance with the SBP strategy, with the aim of excluding
an initial bladder preservation rate of <60%. This stop/go
criterion was based on a single-arm phase II design and
required 39/55 patients in the SBP arm to undergo RT
following response to neoadjuvant chemotherapy to warrant
continuation to phase III.
Statistical Analysis
All randomised patients are included. The number of
neoadjuvant chemotherapy responses was compared between
groups using Fisher’s exact test. Compliance with allocated
treatment strategy was assessed by the proportion of patients:
(i) with response after CT3 who received CT4 neoadjuvant
chemotherapy and (ii) undergoing allocated treatment as their
deﬁnitive treatment overall (i.e. RC in the RC arm, bladder
preservation in SBP arm responders and RC in SBP arm non-
responders). In the SBP group, the bladder preservation rate
was the proportion of patients who did not require RC after
RT both overall and in the subset who received RT according
to protocol guidelines, i.e. in the population who responded
to chemotherapy and received CT4. Unless otherwise stated,
proportions are presented with exact binomial 95% CIs.
Worst grade adverse events were compared by deﬁnitive
treatment received and time to grade 3–4 event was estimated
using Kaplan–Meier methods.
Time-to-event endpoints were assessed using Kaplan–Meier
methods in the population of responders in both groups, and
repeated according to both intention to treat (ITT) and
deﬁnitive treatment received. Treatment effects were
estimated using unadjusted Cox regression models, with a
hazard ratio <1 indicating beneﬁt for SBP in the ITT analysis
or RT for the treatment received analysis. OS was deﬁned as
time to death from any cause; time to loco-regional
recurrence was calculated to ﬁrst non-muscle invasive bladder
cancer (NMIBC) or MIBC recurrence in the bladder or
recurrence in the pelvic nodes; MFS was time to the ﬁrst of
distant recurrence or death; disease-speciﬁc survival was time
to death following nodal or metastatic recurrence or
unsalvageable local recurrence. All times are calculated from
randomisation.
Quality-of-life data were analysed by treatment received and
data were scored and missing data handled in accordance
with the EORTC QLQ-C30 scoring manual [19]. For each
QLQ-C30 subscale, the mean change from baseline was
calculated, with 99% CI, for each group at each time point
and longitudinal plots of change from baseline were
produced. Differences between groups in mean change from
baseline to 12 months were assessed using analysis of
covariance (ANCOVA), adjusting for baseline score.
Analyses are based on a snapshot of the database taken on
30th September 2014 and performed using Stata (Stata
Statistical Software: release 13; StataCorp., College Station,
TX, USA) [20].
Research Governance
SPARE was funded by Cancer Research UK (CRUK/07/011,
C1491/A9895). The study is registered (ISRCTN61126465),
sponsored by the ICR, and approved by the South East
Multicentre Research Ethics Committee. SPARE was managed
by a multidisciplinary trial management group and overseen
by Independent Data Monitoring (IDMC) and Trial Steering
(TSC) committees.
Results
Patient Screening and Recruitment
The ﬁrst patient was recruited on 20/07/2007 and the trial
closed to recruitment on 12/02/2010 with 45 patients accrued
on the advice of the IDMC and TSC due to failure to achieve
target (stop/go) accrual rates.
Participating sites were requested to submit anonymised
screening logs to the central coordinating centre on a regular
basis throughout recruitment, to report patients with T2–3
N0 M0 bladder cancer who may be eligible for the trial. In
all, 796 patients were reported, of whom 490 were ineligible,
most of whom were not ﬁt enough to receive all three SPARE
treatment modalities (chemotherapy, RC and RT). A further
141 potentially eligible patients were not approached about
participation, largely due to the complexity of the patient
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referral pathway, which meant that they were not identiﬁed
as potentially eligible by the participating centre prior to
radical treatment commencing [21].
In all, 45/165 patients approached to participate consented,
with 25 allocated to the RC group and 20 to SBP group. Of
the 120 patients approached who declined, RT was preferred
by 51 and RC by 25 (unknown 44) (Fig. 2).
Baseline Characteristics and Compliance with
Allocated Treatment
In all, 23/23 (100%) RC patients (two missing) and 17/20
(85%) SBP patients responded to neoadjuvant chemotherapy
(P = 0.092) (Table 1). In all, 35 of these 40 patients with a
response to neoadjuvant chemotherapy received CT4 in
accordance with the protocol.
Deviations from protocol deﬁned treatment were
frequent (Fig. 2). In all, 36/45 (80.0%, 95% CI 65.4–
90.4%) received deﬁnitive treatment according to
allocated group. Whilst, 19/25 (76%, 95% CI 54.9–
90.6%) patients allocated RC underwent RC, with six
(24%) receiving RT.
In the SBP group, 17/20 (85.0%, 95% CI 62.1–96.8%) received
protocol deﬁned treatment; 15/20 SBP patients (75%, 95% CI
50.9–91.3%) responded to neoadjuvant chemotherapy and
received RT per protocol and two of the 20 patients (10%,
95% CI 1.2–31.7%) did not respond to chemotherapy and
proceeded to RC per protocol. The other three patients were
not treated in accordance with the SBP strategy: one non-
responder had RT after CT3 rather than proceeding to RC;
two responded yet had RC (one after CT3 and one after CT4
of neoadjuvant chemotherapy).
In all, 22 participants overall (16 SBP; six RC) received RT,
two with concomitant radiosensitisation. Five of the 22
(22.7%; 95% CI 7.8–45.4%) RT recipients subsequently
underwent salvage RC, all due to recurrent bladder cancer
(three MIBC, two NMIBC). The long-term bladder
preservation rate in the SBP group was 12/20 (60%) and was
11/15 (73%) in those SBP patients who received RT per
protocol.
Toxicity
More patients undergoing RC had CTCAE grade 3–4 toxicity
[16/23 (70%) for RC; eight of 22 (36%) for RT; P = 0.038;
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which was 12/23 (52%) and six of 22 (27%) respectively, if
erectile dysfunction is excluded] (Table 2, Fig. 3). The most
common CTCAE grade 1–4 toxicity in patients undergoing
RC was fatigue [15/23 (65%)]; and in patients receiving RT
was fatigue and nocturia [both 12/22 (55%)].
Cancer Control and Survival
The median (interquartile range) follow-up was 58.0 (44.3–
61.3) months. The hazard ratio for the randomised
comparison of OS was 3.05 (95% CI 0.92–10.15; Fig. 4).
Considering groups deﬁned by deﬁnitive treatment received
gave a hazard ratio of 1.83 (95% CI 0.55–6.07; Fig. S1). Given
the wide CIs of the estimate, a survival difference between
groups can be neither conﬁrmed nor excluded and non-
inferiority cannot be claimed.
The loco-regional recurrence rate at 2 years was lower in
patients randomised to RC at 15.3% (95% CI 5.2–40.5%) vs
68.9% (95% CI 42.5–91.5%) in the SBP group (Fig. 4). Seven
Table 1 Baseline characteristics and compliance with allocated
treatment.
Characteristic RC SBP (RT) Total
Number of patients 25 20 45
Tumour characteristics
Gender, n (%)
Male 22 (88) 18 (90) 40 (89)
Female 3 (12) 2 (10) 5 (11)
Age
Mean (SD) 67.6 (6.1) 63.3 (8.5) 65.7 (7.5)
Median
(min, max)
67 (58.2, 81.1) 63.2 (37.9, 75.2) 65.3 (37.9, 81.1)
Patient characteristics
Clinical stage, n (%)
T2 22 (88) 14 (70) 36 (80)
T3a 0 (0) 2 (10) 2 (4)
T3b 1 (4) 2 (10) 3 (7)
Missing 2 (8) 2 (10) 4 (9)
Pathological stage, n (%)
pT1 1 (4) 1 (5) 2 (4)
pT2 24 (96) 19 (95) 43 (96)
Tumour grade, n (%)
G2 1 (4) 3 (15) 4 (9)
G3 24 (96) 17 (85) 41 (91)
Type of chemotherapy, n (%)
Gem-Cis 24 (96) 20 (100) 44 (98)
Other
(Gem-Carbo)
1 (4) 0 (0) 1 (2)
Compliance with allocated treatment, n (%)*
Responder 23 (92) 17 (85) 40 (89)
RC 18 (72) 2 (10) 20 (44)
RT 5 (20) 15 (75) 20 (44)
Non-responder 0 (0) 3 (15) 3 (7)
RC – (–) 2 (10) 2 (4)
RT – (–) 1 (5) 1 (2)
Response data
missing
2 (8) 0 (0) 2 (4)
RC 1 (4) – (–) 1 (2)
RT 1 (4) – (–) 1 (2)
Greyed cells indicate correct deﬁnitive treatment based on allocation and response to
chemotherapy. *Figures in bold are numbers according to randomised groups, ﬁgures
in italics indicate numbers according to treatment received.
Table 2 Worst overall toxicity grade by treatment received for all patients.
CTCAE v3 grade RC, N (%)
(N = 23)
SBP (RT), N (%)
(N = 22)
Total, N (%)
(N = 45)
All
0 0 (0) 0 (0) 0 (0)
1 2 (9) 6 (27) 8 (18)
2 5 (22) 8 (36) 13 (29)
3 10 (43) 8 (36) 18 (40)
4 6 (26) 0 (0) 6 (13)
Total grade 0–2 7 (30) 14 (64) 21 (47)
Total grade 3–4* 16 (70) 8 (36) 24 (53)
Excluding ED
0 0 (0) 0 (0) 0 (0)
1 4 (17) 7 (30) 11 (48)
2 7 (30) 9 (39) 16 (70)
3 6 (26) 6 (26) 12 (52)
4 6 (26) 0 (0) 6 (26)
Total grade 0–2 11 (48) 16 (70) 27 (117)
Total grade 3–4† 12 (52) 6 (26) 18 (78)
ED, erectile dysfunction. *Two-sided Fisher’s exact test comparing number grade 3–4
events between the two groups P = 0.038. †Two-sided Fisher’s exact test comparing
number grade 3–4 events between the two groups P = 0.130.
Median time to event (months):
RC: 25.5 (11.2, 49.6)
RT: not reached
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received and (b) when excluding erectile dysfunction.
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patients in the SBP group developed NMIBC recurrence, of
whom ﬁve are long-term survivors after salvage treatment.
There was no evidence of difference in MFS (Fig. 4) or
disease-speciﬁc survival between randomised groups.
Quality of Life
Baseline subscale scores were similar between the groups.
After 12 months, patients who received RT showed
improvement in mean global health status and social
functioning, whilst these declined in the RC group (Table 3).
However, the conﬁdence limits of the estimates of differences
between groups are wide (Fig. 5). Changes over time in the
QLQ-BLM30 single items scores suggest a decline in body
image and male sexual problems after RC that is less evident
in RT patients (Fig. 6). With both treatments there is an
improvement in future perspectives with time.
Discussion
SPARE closed due to failure to meet the predeﬁned minimum
target recruitment rate, even though there had been extensive
efforts and qualitative research to support recruitment
[15,16,21].
One key criterion for assessing feasibility of phase III was to
demonstrate acceptability of the randomised treatment
strategies and viability of use of chemotherapy response to
select patients for RT. At least 60% of those in the SBP group
were anticipated to receive RT per protocol. Whilst an initial
bladder preservation rate of 75% was seen in those receiving
RT per protocol in the SBP arm, the small number of
patients recruited resulted in wide CIs spanning 60%, such
that the threshold to warrant continuation to phase III was
not met. A 90% RC rate was anticipated in the RC group but
RC was only performed in 76% of patients in this group.
Low randomisation rates and frequent deviations from
allocated treatment suggest patients have a reluctance to allow
randomisation to determine which of two contrasting
treatment strategies they should receive. In accordance with
the principles of good clinical practice, patients were made
aware before randomisation that they could change their
mind about participation in the trial at any stage without
affecting the level of care they would receive. However, they
were asked not to join the trial unless they thought they
would be willing for their treatment to be determined by the
SPARE protocol. Despite this request, a high proportion of
treatment deviations, largely driven by patient choice, were
observed.
An additional contributor to early closure of the study was
the smaller than anticipated number of patients eligible for all
treatment modalities. This, in addition to a lack of equipoise
amongst clinicians [16], had a major impact. Undoubtedly, a
proportion of patients approached for the present study
showed an appetite for bladder preservation; many selecting
RT when declining randomisation and a substantial
proportion of participants receiving RT when not mandated
by the protocol. This suggests that patients’ wishes for
bladder preservation should be considered when discussing
treatment options.
Robust conclusions cannot be made due to the limited
sample size and are further complicated by poor compliance
with assigned treatment strategy and differences in
neoadjuvant chemotherapy response rates between the two
Table 3 Change in EORTC QLQ C30 subscale scores from baseline to month 12.
RC SBP (RT) RC vs SBP (RT)
N Mean change
from baseline
99% CI N Mean change
from baseline
99% CI Difference*
(SBP – RC)
99% CI
Global health status 18 11.6 31.9 to 8.7 12 7.64 11.9 to 27.1 14.2 11.1 to 39.5
Physical function 18 10 23.9 to 3.9 10 2.67 22.9 to 17.6 7.76 13.9 to 29.4
Role function 18 8.3 32.8 to 16.1 12 0 25.5 to 25.5 15.27 16.3 to 46.9
Emotional function 18 6.5 6.4 to 19.4 12 6.25 7.3 to 19.8 3.03 11.9 to 18.0
Cognitive function 18 6.5 4.7 to 17.6 12 2.78 16.8 to 11.2 2.59 14.5 to 9.3
Social function 18 7.4 35.1 to 20.3 12 4.17 25.8 to 34.1 16.62 16.6 to 49.9
Fatigue 16 4.9 28.4 to 18.7 12 11.11 35.5 to 13.3 9.28 33.2 to 14.7
Nausea/vomiting 18 7.4 17.2 to 2.3 12 0 14.3 to 14.3 5.46 8.3 to 19.2
Pain 18 1.9 13.7 to 17.4 11 0 14.2 to 14.2 2.71 19.4 to 14.0
Dyspnoea 18 0 17.5 to 17.5 11 3.03 12.6 to 6.6 3.47 23.7 to 16.8
Insomnia 18 5.6 34.0 to 22.9 12 2.78 26.5 to 20.9 7.72 38.0 to 22.5
Appetite loss 18 0 13.5 to 13.5 12 2.78 26.5 to 20.9 3.53 23.5 to 16.4
Constipation 18 7.4 30.3 to 15.4 12 2.78 29.6 to 35.2 2.86 32.5 to 26.8
Diarrhoea 18 0 7.8 to 7.8 12 0 12.7 to 12.7 0.69 11.2 to 9.8
Financial problems 18 3.7 14.4 to 7.0 12 0 0 to 0 1.68 10.8 to 14.1
CIs were constructed using Student’s t-distribution. No P values were calculated. High scores indicate better function for functional subscales, and high scores indicate worse
symptoms/more problems for all other scales. *ANCOVA difference in the change in 12-month subscale score from baseline between patients receiving SBP (RT) and patients
receiving RC as deﬁnitive treatment, adjusting for baseline subscale score.
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B/L: baseline; P/T: post-treatment
Note: high scores indicate better function
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Fig. 5 Mean change from baseline in EORTC QLQ-C30 subscales.
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Fig. 6 Mean change from baseline in EORTC QLQ-BLM30 subscales.
© 2017 The Authors.
BJU International published by John Wiley & Sons Ltd on behalf of BJU International 9
Clinical and patient-reported outcomes of spare
randomised groups. Overall response to neoadjuvant
chemotherapy was consistent with pilot work [14] and was
higher than the pathological complete response rates in RC
specimens reported in trials of neoadjuvant chemotherapy
followed by RC [10,22]. This would suggest that cystoscopic
examination under stages some patients and supports the
rationale for recommending additional treatment even for a
clinically normal-looking bladder.
Loco-regional recurrence-free survival was worse after RT,
mainly due to the incidence of NMIBC, which was more
frequent than invasive recurrence. This is reported in other
bladder preserving series [14,23,24] and suggests the bladder
remains at high risk of developing second primary disease.
This may indicate a role for preventative therapy such as that
undertaken for NMIBC. Many cases of NMIBC can be
salvaged with local treatment, thus the bladder preservation
rate remained high as reported elsewhere [14,24].
When comparing radical RT to RC, considering the
frequency of ‘non-salvageable’ recurrences may be more
appropriate than overall recurrence rates. In the present
study, the rate of non-salvageable recurrences in responders
to neoadjuvant chemotherapy is similar for RC (four of 23)
and SBP (ﬁve of 17), as are OS and MFS. Observations from
the present randomised trial are consistent with the results of
population-based studies [7,25–27], non-randomised single-
institution studies [6], and cross study comparisons [4],
showing little evidence of inferior survival after SBP when
compared to RC. A recent review of chemo-RT studies for
MIBC reported bladder cancer-speciﬁc survival and OS rates
of 50–82% and 36–74%, respectively [28]; similar to those
seen in like-for-like RC series. If, as our present results
suggest, RT has less impact on quality of life than RC, this
would provide additional rationale for consideration of
bladder-sparing therapy.
Few RT recipients had concomitant chemo-RT, which has
since been shown to signiﬁcantly improve clinical outcomes
[23]. The technical delivery of RT has also improved with the
advent of adaptive and image-guided techniques [29–31], so
one may expect improved outcomes with RT in the future.
Likewise developments in surgery with increasing use of
bladder reconstruction, enhanced recovery pathways [32], and
minimally invasive techniques [33,34], should result in
beneﬁts for patients.
The poor outcome of patients, whose tumours did not
respond to neoadjuvant chemotherapy, whether or not they
underwent RC, remains a concern and has been seen in other
studies [14]. Alternative systemic or palliative treatment
options should perhaps be explored in this population.
Identiﬁcation of predictive markers to help select patients for
whom organ preservation may be a suitable option remains
important. Recent work suggests that bladder cancer may
consist of a variety of genetic sub-types. It would be of
interest to understand if certain of these subtypes are more or
less likely to respond to chemotherapy or RT [35].
Alternative candidates may be markers of DNA repair, with
recently published work on MRE11 (meiotic recombination
11 homolog) and TIP60 (tat-interactive protein) showing
promising initial results [36,37]. These markers will need to
be validated and then tested prospectively. Given experiences
in SPARE, design of any such study will need to consider the
powerful inﬂuence of patient and clinician preferences and
issues of equipoise.
Conclusions
A randomised phase III trial comparing SBP and RC after
neoadjuvant chemotherapy was not feasible. Due to the small
number of patients, ﬁrm conclusions about disease and
toxicity outcomes following these interventions cannot be
drawn, although high rates of bladder preservation appear to
be achievable in chemotherapy responders without
compromising OS.
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